14.4 Cumulative Antibiogram Construction and CLSI M39 Analysis

Board Certified Infectious Diseases Pharmacist BCIDP

Track your progress as you read

Finished sections get a check mark.

1 Causes of Infectious Diseases

1.1 Bacterial Pathogens: Gram-Positive, Gram-Negative, and Atypical Organisms 1.2 Viral Pathogens: Respiratory, Herpesviruses, Hepatitis, and Emerging Viruses 1.3 Fungal Pathogens: Yeasts, Molds, and Dimorphic Fungi 1.4 Parasitic and Vector-Borne Pathogens: Protozoa and Helminths

2 Microbiology Diagnostics, Resistance & Host Response

2.1 Diagnostic Microbiology: Phenotypic, Molecular, and Rapid Diagnostic Methods 2.2 Molecular Mechanisms of Antimicrobial Resistance 2.3 Microbial Virulence Factors, Toxins, and Biofilm Dynamics 2.4 Host Immune Response to Infection and Immunopathology

3 Clinical Assessment & Diagnostic Evaluation

3.1 Clinical Assessment, Infection Screening, and Severity Stratification 3.2 Diagnostic Biomarkers and Clinical Laboratory Interpretation 3.3 Social Determinants of Health and Disparities in Infectious Diseases

4 Pharmacokinetics, Pharmacodynamics & Special Populations

4.1 Pharmacokinetic and Pharmacodynamic Optimization of Antimicrobials 4.2 Host and Environmental Risk Factors for Infection 4.3 Antimicrobial Dosing and Considerations in Special Populations

5 Respiratory and Skin/Soft Tissue Infections

5.1 Pharmacotherapy of Upper and Lower Respiratory Tract Infections 5.2 Pharmacotherapy of Skin and Soft Tissue Infections

6 Cardiovascular, Bone, and Joint Infections

6.1 Pharmacotherapy of Infective Endocarditis and CIED Infections 6.2 Pharmacotherapy of Osteomyelitis, Septic Arthritis, and PJI

7 Central Nervous System and Abdominal Infections

7.1 Pharmacotherapy of Central Nervous System Infections 7.2 Pharmacotherapy of Intra-abdominal, Hepatic, and GI Infections

8 Urologic, Gynecologic, and Sexually Transmitted Infections

8.1 Pharmacotherapy of Urinary Tract and Gynecologic Infections 8.2 Pharmacotherapy of Sexually Transmitted Infections

9 HIV Infection and Opportunistic Infections

9.1 Antiretroviral Therapy and Management of HIV-1 Infection 9.2 Prophylaxis and Management of HIV-Associated Opportunistic Infections

10 Infections in Immunocompromised Hosts and Complex Syndromes

10.1 Infections in Solid Organ Transplant and Hematologic Malignancy 10.2 Sepsis, Septic Shock, and Systemic Complications

11 Medication Administration and Adjunctive Therapies

11.1 Antimicrobial Administration, Vascular Access, and Stability 11.2 Adjunctive Pharmacotherapies and Supportive Care in Serious Infections 11.3 Assessment of Therapeutic Outcomes and Infection Failure

12 Therapeutic Drug Monitoring, Toxicity, and De-escalation

12.1 Therapeutic Drug Monitoring and Precision Pharmacokinetics 12.2 Antimicrobial Adverse Drug Events and High-Risk Drug Interactions 12.3 Antimicrobial De-escalation and IV-to-Oral Transition Strategies

13 Care Transitions, Patient Counseling & Travel Medicine

13.1 Outpatient Parenteral and Complex Oral Antimicrobial Therapy (OPAT/COPAT) 13.2 Patient and Caregiver Counseling, Education, and Adherence 13.3 Travel Medicine, Immunizations, and Prophylactic Regimens

14 Antimicrobial Stewardship Operations, Metrics & Resistance

14.1 Antimicrobial Stewardship Core Elements and Regulatory Mandates 14.2 Stewardship Metrics: Days of Therapy (DOT), DDD, and SAAR 14.3 Surveillance and Tracking of Antimicrobial Resistance Patterns 14.4 Cumulative Antibiogram Construction and CLSI M39 Analysis

15 Formulary Management, Infection Prevention & Population Health

15.1 Antimicrobial Formulary Management and Restriction Strategies 15.2 Public Health, Disease Reporting, and Adult Immunization Strategies 15.3 Healthcare Infection Prevention and Environmental Transmission

16 Literature Evaluation, Informatics & Quality Improvement

16.1 Infectious Diseases Information Resources, Databases, and Clinical Guidelines 16.2 Critical Literature Evaluation and Biostatistical Interpretation 16.3 Quality Improvement Methodologies and Medication Safety in ID 16.4 Clinical Informatics, Decision Support Systems, and Automated Alerts

14.4 Cumulative Antibiogram Construction and CLSI M39 Analysis

Key Takeaways Explain This Topic AI

The Clinical and Laboratory Standards Institute (CLSI) M39 document establishes the gold standard methodology for cumulative antibiograms, mandating at least annual reporting using the first-isolate-per-patient rule.

The first-isolate-per-patient rule requires including only the initial isolate of a given species recovered from a patient during the 12-month analysis window, completely eliminating duplicate culture bias from chronically infected patients.

A minimum statistical threshold of at least 30 isolates ( N ≥ 30 N \ge 30 N ≥ 30 ) is required to report susceptibility percentages; data for species with < 30 < 30 < 30 isolates should be suppressed or flagged with explicit warnings due to unreliable confidence intervals.

Stratified antibiograms (e.g., ICU vs non-ICU, urine vs non-urine, inpatient vs outpatient) unmask localized resistance reservoirs that are obscured by aggregated hospital-wide data.

Antibiogram interpretation traps include failing to recognize intrinsic resistance, ignoring inducible AmpC beta-lactamases in 'SPACE/SPICE' organisms, and misinterpreting delayed automated testing breakpoint updates.

Last updated: October 2026

Cumulative Antibiogram Construction and CLSI M39 Analysis

The cumulative antibiogram is an essential clinical, stewardship, and epidemiological tool that aggregates local antimicrobial susceptibility testing (AST) data into an institutional summary table. By displaying the overall percentage of bacterial isolates susceptible to various antimicrobials, the antibiogram guides clinicians in selecting optimal empiric therapy, supports stewardship teams in developing local clinical practice guidelines and formulary restrictions, and tracks longitudinal shifts in institutional resistance. To ensure statistical validity and clinical accuracy, cumulative antibiograms must be constructed in strict accordance with the Clinical and Laboratory Standards Institute ( CLSI ) M39 document: Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data .

The Methodological Pillars of CLSI M39 CLSI M39 FOUR METHODOLOGICAL PILLARS

1. REPORTING WINDOW 2. FIRST-ISOLATE RULE 3. SAMPLE THRESHOLD 4. SUSCEPTIBILITY CALC
┌──────────────────────┐ ┌──────────────────────┐ ┌──────────────────────┐ ┌──────────────────────┐
│ • At least annual │ │ • Include ONLY first │ │ • Minimum N ≥ 30 │ │ • Numerator: S only │
│ (12-month period) │ ───► │ isolate of species │ ───► │ isolates required │ ───► │ • Denominator: S+I+R │
│ • Captures seasonal │ │ per patient per yr │ │ • If N < 30: suppress│ │ • Exclude Intermediate│
│ variation │ │ • Eliminates skew │ │ or multi-year pool │ │ • Round to whole % │
└──────────────────────┘ └──────────────────────┘ └──────────────────────┘ └──────────────────────┘
1. Analysis Window / Timeframe

Antibiograms must be generated at least annually , compiling 12 continuous months of diagnostic testing data.

Analyzing data over a full 12-month period balances statistical power against temporal relevance. It captures seasonal variation (e.g., winter peaks in Streptococcus pneumoniae or summer spikes in enterococcal infections) while preventing short-term sampling artifacts. Compiling data more frequently than annually (e.g., quarterly) is discouraged unless isolate numbers are vast, as small sample sizes generate volatile, misleading swings in susceptibility.

2. The First-Isolate-per-Patient Rule

The Rule: Include only the first isolate of a given species recovered from an individual patient during the 12-month analysis window , irrespective of body source, anatomical site, or antimicrobial susceptibility profile.

The Rationale (Eliminating Duplicate Culture Bias): Inpatient populations include chronically hospitalized patients, individuals with cystic fibrosis, recurrent urinary tract infections, chronic osteomyelitis, or non-healing decubitus ulcers who undergo repeated microbiological cultures over weeks or months. These repeated cultures overwhelmingly yield highly resistant, extensively treated organisms. If all repeat isolates were included:

The antibiogram would become heavily skewed toward artificial hyper-resistance.

Clinicians would be misled into concluding that first-line, narrow-spectrum agents are ineffective, driving unnecessary empiric escalation to ultra-broad-spectrum reserve antibiotics.

Application Across Multiple Species: The rule applies on a species-by-species basis . If a patient has a blood culture yielding Escherichia coli in January and another culture yielding Klebsiella pneumoniae in March, both isolates are included (as each represents the first isolate of that specific species for that patient). However, if the same patient grows E. coli from urine in January, from blood in February, and from sputum in April, only the January urine E. coli isolate is included in the cumulative antibiogram.

3. Minimum Isolate Threshold ( N ≥ 30 N \ge 30 N ≥ 30 )

Statistical Rationale: Susceptibility percentages derived from small sample sizes possess wide 95% binomial confidence intervals, making them statistically unreliable for clinical decision-making.

If an organism has N = 10 N = 10 N = 10 isolates and 8 are susceptible ( 80 % 80\% 80% ), the true 95 % 95\% 95% confidence interval spans from 44 % 44\% 44% to 97 % 97\% 97% .

At N = 30 N = 30 N = 30 isolates with 80 % 80\% 80% susceptibility, the 95 % 95\% 95% confidence interval narrows to 61 % 61\% 61% to 92 % 92\% 92% , providing an acceptable statistical baseline.

Management of Organisms with N < 30 N < 30 N < 30 :

CLSI strongly recommends excluding or suppressing species with fewer than 30 isolates from the public antibiogram.

Acceptable Alternatives: (1) Pool cumulative data across consecutive years (e.g., 24 to 36 months) until N ≥ 30 N \ge 30 N ≥ 30 is achieved; or (2) Publish the data with a prominent footnote or distinct typographical warning indicating that the sample size is < 30 < 30 < 30 and the reported rate is statistically imprecise.

4. Calculation and Rounding of Percent Susceptible

Formula: % Susceptible = ( Number of Susceptible (S) Isolates Total Number of Tested Isolates (S + I/SDD + R) ) × 100 \%\text{ Susceptible} = \left( \frac{\text{Number of Susceptible (S) Isolates}}{\text{Total Number of Tested Isolates (S + I/SDD + R)}} \right) \times 100 % Susceptible = ( Total Number of Tested Isolates (S + I/SDD + R) Number of Susceptible (S) Isolates ) × 100

Handling Intermediate (I) and Susceptible-Dose Dependent (SDD):

Isolates categorized as Intermediate (I) or Susceptible-Dose Dependent (SDD) must NEVER be counted in the numerator as susceptible. They are counted strictly in the denominator.

Lumping Intermediate isolates with Susceptible isolates falsely inflates perceived drug efficacy.

Rounding Rule: The calculated percentage must be rounded to the nearest whole percentage point (e.g., 89.5 % 89.5\% 89.5% rounds to 90 % 90\% 90% ; 89.4 % 89.4\% 89.4% rounds to 89 % 89\% 89% ). Decimals should not be displayed, as they convey a false impression of mathematical precision.

CLSI M39 Core Rule Methodological Requirement Clinical Consequence of Non-Compliance

Timeframe 12 continuous months of cumulative data Quarterly reports yield small N N N and erratic, volatile rates

First-Isolate Rule First isolate of species per patient per year Repeat cultures from chronic patients falsely exaggerate resistance

Threshold ( N ≥ 30 N \ge 30 N ≥ 30 ) Minimum 30 isolates per reported species Wide confidence intervals lead to erroneous clinical decisions

Calculation Numerator = Susceptible (S) only Including Intermediate (I) overestimates clinical efficacy

Rounding Round to nearest whole integer ( 0 – 100 % 0–100\% 0–100% ) Displaying decimals implies unvalidated statistical precision

Stratified, Syndromic, and Specialized Antibiograms

While a facility-wide aggregate antibiogram provides an institutional overview, it often obscures critical unit-specific resistance reservoirs. A hospital-wide Pseudomonas aeruginosa susceptibility to cefepime of 88% may conceal an intensive care unit (ICU) susceptibility of only 70% alongside a general medical ward susceptibility of 93%. To overcome this limitation, CLSI M39 provides standards for stratified and specialized antibiograms: SPECIALIZED ANTIBIOGRAM TYPOLOGIES

ANATOMIC / SYNDROMIC STRATIFICATION UNIT / POPULATION STRATIFICATION
┌────────────────────────────────────────┐ ┌────────────────────────────────────────┐
│ • Urine vs Non-Urine Antibiograms │ │ • Inpatient vs Outpatient / ED │
│ • Bloodstream Isolates (Bacteremia) │ │ • Adult ICU vs Non-ICU Medical Wards │
│ • Respiratory / BAL Antibiograms │ │ • Pediatric / NICU Specialized Tables │
└────────────────────────────────────────┘ └────────────────────────────────────────┘
1. Inpatient vs. Outpatient / Emergency Department Stratification

Outpatient isolates generally exhibit significantly higher susceptibility to oral beta-lactams and fluoroquinolones compared to nosocomial isolates. Conflating outpatient emergency department data with inpatient ward data misleads emergency physicians into over-prescribing broad-spectrum inpatient agents for uncomplicated community infections.

2. ICU vs. Non-ICU Stratification

Critical care units harbor intense antimicrobial selection pressure, prolonged indwelling device days, and sicker patient populations. Stratifying data into ICU versus Non-ICU tables is standard practice in hospitals with ≥ 100 \ge 100 ≥ 100 beds, ensuring empiric septic shock regimens are tailored to critical care resistance realities.

3. Anatomic Specimen Stratification: Urine vs. Non-Urine

Clinical Rationale: The urinary tract represents the most common source of clinical cultures. E. coli isolates from uncomplicated cystitis display vastly different resistance patterns and utilize different clinical breakpoints than bloodstream isolates.

Reporting Specifics: Agents indicated exclusively for lower urinary tract infections (e.g., nitrofurantoin, fosfomycin ) must be reported only on the urine antibiogram . Displaying nitrofurantoin on a general or blood antibiogram risks catastrophic clinical error if a prescriber attempts to treat systemic urosepsis or pyelonephritis with nitrofurantoin (which achieves therapeutic concentrations only in the urinary bladder lumen, with zero renal parenchymal or serum tissue penetration).

Breakpoint Discrepancies: CLSI establishes distinct urinary versus systemic breakpoints for cefazolin against Enterobacterales (urinary breakpoint ≤ 16 mcg/mL \le 16\text{ mcg/mL} ≤ 16 mcg/mL as a surrogate for oral agents in uncomplicated UTI vs systemic bloodstream breakpoint ≤ 2 mcg/mL \le 2\text{ mcg/mL} ≤ 2 mcg/mL ). Specimen stratification is essential to reflect these differences accurately.

4. Combination Antibiograms (Synergy / Dual-Susceptibility Tables)

In critically ill patients with suspected multidrug-resistant Gram-negative bacteremia or ventilator-associated pneumonia ( Pseudomonas aeruginosa , Acinetobacter baumannii ), no single agent achieves > 90 % > 90\% > 90% empiric coverage on the standard antibiogram.

Methodology: A combination antibiogram displays the percentage of isolates susceptible to at least one of two concurrent agents when tested together: % Coverage = Isolates Susceptible to Drug A OR Drug B Total Isolates Tested × 100 \%\text{ Coverage} = \frac{\text{Isolates Susceptible to Drug A OR Drug B}}{\text{Total Isolates Tested}} \times 100 % Coverage = Total Isolates Tested Isolates Susceptible to Drug A OR Drug B × 100

Example: In an ICU with high Pseudomonas resistance, cefepime monotherapy covers 75 % 75\% 75% of isolates and tobramycin monotherapy covers 80 % 80\% 80% . A combination antibiogram demonstrates that combining cefepime PLUS tobramycin achieves 94 % 94\% 94% susceptibility , providing statistical validation for dual empiric coverage in septic shock pending definitive susceptibility results.

Antibiogram Interpretation Traps and Clinical Pitfalls

Even a methodologically flawless antibiogram can be misinterpreted by clinicians. Infectious diseases specialists and ASP leaders must recognize and educate prescribers regarding key clinical traps:

1. Intrinsic Antimicrobial Resistance

An antibiogram must never display an antimicrobial as "susceptible" if the organism possesses innate, natural resistance mechanisms, regardless of in vitro testing artifacts:

Stenotrophomonas maltophilia : Intrinsically resistant to all carbapenems via chromosomal L1 metallo-beta-lactamase and L2 serine beta-lactamase.

Proteus , Providencia , and Morganella spp.: Intrinsically resistant to nitrofurantoin, tigecycline, and colistin/polymyxins.

Klebsiella pneumoniae : Intrinsically resistant to ampicillin via chromosomal SHV-1 beta-lactamase.

Enterococcus faecalis / E. faecium : Intrinsically resistant to all cephalosporins, trimethoprim-sulfamethoxazole, and clindamycin (in vitro susceptibility does not translate into in vivo clinical efficacy).

Serratia marcescens : Intrinsically resistant to colistin and polymyxin B.

2. Inducible AmpC Beta-Lactamases ("SPACE / SPICE" Organisms)

High-Risk Organisms: Enterobacter cloacae complex, Klebsiella aerogenes , and Citrobacter freundii carry inducible, chromosomal ampC beta-lactamase genes.

The Clinical Trap: When tested in vitro prior to antibiotic exposure, wild-type isolates possess low basal AmpC production and appear fully susceptible to third-generation cephalosporins (ceftriaxone, ceftazidime) on the standard antibiogram. However, exposure to ceftriaxone in vivo induces transcription or selects for stably derepressed ampC mutants at a frequency of 8 % 8\% 8% to 40 % 40\% 40% during therapy, leading to rapid clinical failure.

Stewardship Rule: Antibiograms must include explicit annotations warning clinicians NOT to use ceftriaxone or ceftazidime for invasive infections caused by E. cloacae , K. aerogenes , or C. freundii , regardless of in vitro susceptibility. Preferred agents are cefepime (stable against AmpC hydrolysis due to its zwitterionic structure and low steric affinity) or a carbapenem . INDUCIBLE AmpC SELECTION PHENOMENON

INITIAL IN VITRO TESTING IN VIVO POST-EXPOSURE (DAY 3 - 5)
┌──────────────────────────────────────┐ ┌──────────────────────────────────────┐
│ • Low basal AmpC enzyme expression │ │ • Ceftriaxone selects for stably │
│ • Culture reads: CEFTRIAXONE = 'S' │ ───► │ derepressed AmpC mutants │
│ • Clinician initiates ceftriaxone │ (Failure!) │ • Massive AmpC enzyme production │
│ │ │ • Ceftriaxone hydrolyzed → RESISTANT │
└──────────────────────────────────────┘ └──────────────────────────────────────┘
*STEWARDSHIP MANDATE: Use Cefepime or Carbapenem for E. cloacae, K. aerogenes, C. freundii*
3. Inappropriate Extrapolation to Polymicrobial Infections

Antibiogram probabilities cannot be multiplied together to determine the coverage of mixed intra-abdominal or diabetic foot infections. A regimen must provide reliable coverage across each anticipated anatomical compartment and pathogen class.

4. Delayed Commercial Breakpoint Updates

When CLSI or the FDA lowers a susceptibility breakpoint (e.g., lowering the ciprofloxacin breakpoint for Enterobacterales from ≤ 1 mcg/mL \le 1\text{ mcg/mL} ≤ 1 mcg/mL to ≤ 0.25 mcg/mL \le 0.25\text{ mcg/mL} ≤ 0.25 mcg/mL , or lowering the piperacillin-tazobactam breakpoint), commercial automated AST instruments (such as VITEK 2, Phoenix, or MicroScan) often take 3 to 5 years to receive FDA software clearance and hardware updates. Until updated, automated analyzers may report isolates as "susceptible" based on obsolete criteria. Stewardship teams must audit whether their laboratory has implemented current CLSI breakpoints.